Feedback / Questions
cendakimab (CC-93538) - AbbVie, BMS
lirentelimab (AK002) - Allakos
Cinqair (reslizumab) - Merck (MSD), UCB, Teva
Nucala (mepolizumab) - GSK
Fasenra (benralizumab) - AstraZeneca
Dupixent (dupilumab) - Sanofi, Regeneron
http://www.ncbi.nlm.nih.gov/pubmed/35738437
Jun 24, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next